Abstract
INTRODUCTION
GISTs are the most common mesenchymal tumors of the human gastrointestinal tract, previously uniformly classified as smooth muscle tumors. Recently, GISTs have been defined as cellular spindle cell, epithelioid, or occasionally pleomorphic mesenchymal tumors of the gastrointestinal tract(GI) that express the c-kit protein (CD117), as detected using immunohistochemistry. GISTs are strongly and nearly uniformly CD117 positive [1] [2] [3] [4] . Resently, the c-kit mutations in GISTs have been shown to lead to ligand-independent activation of the tyrosine kinase of c-kit [5] . So several questions were suggested: what are the possible relationship of c-kit expression and mutations, the relationship of mutations and malignancy, and the possible specificity of the mutations for GISTs?
A study of larger series of GISTs, revealed that these tumors had a spectrum of clinical behaviors at all sites of their occurrence [6] . Some GISTs are typical benign tumors, and most of them are found incidentally in other conditions, for example, during gall bladder or gynecologic surgery. In constrast, other GISTs metastasize to the liver and disseminate in the peritoneal cavity. Large tumor size, presence of intratumoral necrosis, infiltrative growth pattern in muscularis propria, invasion of mucosa, and high mitotic figures are considered as malignant. However, there is a definite percentage of mitotically inactive tumors that subsequently metastasize, emphasizing the fact that low mitotic count does not rule out a malignant behavior. Therefore, the designation "uncertain malignant potential" applies to a significant number of GISTs.
In this study, we further explored whether the c-kit gene mutations were valuable as an adjunct malignant marker in GISTs and could help to differentiate GISTs from other tumors.
MATERIALS AND METHODS

Cases
Archival paraffin-embedded and frozen tissue samples of 52 GISTs were immunohistochemically analysed for CD117 and CD34. They were mainly obtained from the Department of Pathology, Zhongshan Hospital, Fudan University, and from other pathology departments in Cancer Hospital, Huadong Hospital, and Chongming Center Hospital, etc. Additionally, 28 other tumors were investigated, including 8 leiomyosarcomas of retroperitoneum, 3 leiomyomas of esophagus, 2 schwannomas of stomach, 2 malignant peripheral nerve sheath tumors of intraabdomen, 2 intra-abdominal fibromatoses of intestine, 2 malignant fibrous histiocytomas of intra-abdomen, and 9 adenocarcinomas of GI (of which, 4 were accompanied by GISTs).
Histologic evaluation
One to 14 hematoxylin and esosin-stained slides (median, 4 slides) were reviewed for each case. The following features were recorded in all cases: type of the majority cells (spindle vs epithelioid), skeinoid fibers (extracellular collagen globles), mucosal ulceration. Additionally, other important features included mitoses counted from 50 consecutive high-power fields (HPFs), coagulation necrosis, infiltrative growth pattern, and lymph node involvement. According to the histologic observation, GISTs were divided into 3 groups: small incidental tumors with less 5 cm in diameter or fewer mitoses per 50 HPF were designated as benign, mitotically inactive tumors larger than 5 cm or cellular tumors which had no necrosis and infiltration were designated as uncertain malignant potential, and tumors with active mitotic counts over five per 50HPF or with necrosis, infiltrative growth pattern were designated as malignant.
Immunohistochemistry
Antibodies to the following antigens were used. CD117 (c-kit prooncogene product, polyclonal, 1:70) was purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA, CD34 (QBEND-10, monoclonal, 1:150, DAKO), α-SMA (1A4 monoclonal, 1:200), MSA (HHF35 monoclonal, 1:200), desmin (D33, monoclonal, 1:150), S-100 protein (polyclonal, 1:300), and protein gene product 9.5 (PGP9.5, polyclonal, 1:300) were purchased from Dako Corp. Epitope retrieval was used for antibodies. The slides were immersed in 10 mmol/L citrate buffer, pH 6.0 and heated in a microwave oven at a high setting for 5 min. The EnVision staining technique was used followed by incubation with 3,3'-diaminobenzidine tetrahydrochloride and counterstained with hematoxylin.
DNA extraction
Ten micrometers of tissue sections were cut from freshy frozen tumors or paraffin embedded, and then incubated in extraction buffer (50 mmol/L KCl, 10 mmol/L Tris[pH8.3], 2.5 mmol/L MgCl 2 ) containing 60 µg/mL proteinase K overnight at 55 . The proteinase K was inactivated by a 10-min incubation at 95 . The resulting lysate was spun in a microcentrifuge for 5 min to pellet debris, and then stored at -20 .
PCR amplification of exons 11, 9, and 13 of c-kit gene PCR assays were developed to amplify exons 11, 9, and 13. The 3 primer pairs were designed based on the human c-kit gene. Exons 9, 11 and 13 of the c-kit gene were amplified by PCR using the following oligonucleotide primer pairs: for exon 9, 5'-TCCTAGAGTAAGCCAGGGCTT-3'/ 5'-TGGTAGACAGAGC CTAAACATCC-3'; for exon 11, 5'-CCAGAGTGCTCTAATGA CTG-3'/5'-TGACATGG AAAGCCCCTGTT-3' ; and for exon 13, 5'-GCTTGACATCAGTTTGCCAG-3'/5'-AAA GGCAGCTT GGACACGGCTTTA-3'. The lengths of PCR products were 261 bp, 225 bp, and 193 bp, respectively. The PCR reaction conditions were the standard ones recommended by Perkin Elmer. The annealing temperature was 55 . The PCR products were size fractionated on 50 g/L polyacrylamide gels and stained with ethidium bromide.
DNA sequencing
Direct sequencing was performed on the ABI Prism 310 DNA sequencer, using the same primers as were used for amplification. Sequencing reactions were conducted with the big dye terminator sequencing ready reaction kit (Perkin-Elmer) according to the manufacturer's instructions.
Statistical analysis χ
2 test was used.
RESULTS
Clinicopathological features of GISTs
There were 27 gastric, 7 small intestine, 6 rectal, 5 extra-GI, 2 abdominal disseminated primary tumors, with 5 intraabdominal recurrences. Of these tumors, 8 were classified as histologically benign, 19 as histologically uncertain malignant potential of borderline tumor, and 25 as malignant based on high mitotic activity, coagulative necrosis, infiltrative growth pattern. These tumors displayed a wide variety of cell types and histologic patterns, of which, 34 tumors had a predominant spindle cell pattern, 8 were epithelioid, and 10 were spindle/epithelioid mixed. The spindle cells were most often arranged in interlacing fascicles, The epithelioid cells were characterized by sheets. However, they often showed focally a storiform pattern, mimicked large rosettes, or palisaded the nuclei.
Immunohistochemical findings
CD117 positivity was detected in 50 of 52 cases (96.2%), typically in most of tumor cells in a strong membrane of apparently diffuse cytoplasm. CD34 positivity was seen in 38 of 52 cases (73%), including focal reactive cases. Two CD117-negative cases were CD34 positive. A small number were focal positive for α-SMA (10 of 52), MSA (9 of 52), desmin (2 of 52). Additionally, 6 and 3 cases were reactive for S-100 and PGP9.5. 550 560 570 580 590 Figure 1 Exon 11 of c-kit mutations in 16 GIST samples. The wild-type sequence of amino acids encoded by exon 11 is shown at the top. The sequence starting at codon 550 and ending at 590. The wide-type sequence is shown above, the numbers are shown at the left. Point mutation is shown in black type, deletion is shown in the thin line indicates heterozygote mutation and thick line indicates homozygote ones. the shaded areas correspond to insertion or duplication mutations.
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Evaluation of mutations in exons 11, 9, and 13 of c-kit gene PCR amplification and DNA sequencing revealed exon 11 mutation in 14 malignant GISTs, in 2 borderline GISTs, and in no benign GISTs. Sequence analysis showed in-frame deletions of 3 to 48 bp, point mutations, and duplications. Point mutations and deletions were most frequently observed at codons 550-560, but duplications were most concentrated at codon 570-585. Of the 16 mutated GISTs, 2 had a homozygous mutation and 14 heterozygous mutation, which did not result in any amino acid change. The sequence corresponding to these mutations are shown in Figure 1 . Figure 2 shows a case of duplication by DNA direct sequencing. Five non-tumor tissue samples from the stomach or intestine adjacent to mutation-bearing GISTs demonstrated neither deletions nor point mutations.
The conservation of c-kit mutation pattern was observed in a relapse lesion from the same patients (Figure 3) .
No exon 9 and exon 13 mutation were detected. χ 2 test showed that the c-kit mutation of GISTs demonstrated a statistical (χ 2 =14.39, P<0.01) significance between the malignant group and the borderline and benign groups. 
Other tumors
The three esophageal leiomyomas were histologically paucicellular spindle cell neoplasms with distinctly eosinophilic cytoplasm, and lack of mitotic activity. All cases were positive for α-SMA, MSA and desmin, and negative for CD117 and CD34, and only mast cells in the stroma showed positive CD117.
The 8 retroperitoneal leiomyosarcomas were spindle cell tumors that resembled smooth muscle tumor with oval to mildly elongated nuclei and variably eosinophilic cytoplasm. Four tumors showed focal pleomorphism and high mitotic activity (>50/50HPF). Coagulation necrosis was present in 4 tumors. All cases were positive for α-SMA, MSA, and 7 cases positive for desmin. All cases were negative for CD34 but 1 case was focal weak positive for CD117.
The 2 cases of schwannomas showed slender spindle cells and a characteristic lymphoid cuff. Two cases were diffusely and strongly positive for S-100 and 1 case was positive for PGP9.5. Both of them were negative for CD117 and CD34. The 2 cases malignant peripheral nerve sheath tumor showed spindle cells and active mitosis. Two cases were positive for S-100 and weak positive for PGP9.5 and negative for CD117 and CD34. The 2 cases of intro-abdominal fibromatosis of intestine and 2 cases of malignant fibrous histiocytoma were negative for all antigens but 1 case of intro-abdominal fibromatosis was focal positive for α-SMA.
There were no mutations of the c-kit gene in the above 28 control tumors and one case of adenocarcinoma accompanied by mutation-bearing GIST also had wild-type c-kit gene.
DISCUSSION
Most of the GISTs examined expressed both CD117 and CD34, which was consistent with the literature reports [7] [8] [9] [10] [11] [12] . The rates of CD117 and CD34 expression had no difference between benign, borderline, and malignant GISTs, so the expressions were not useful markers for evaluating malignancy.
In this study, we examined the sequence and expression of c-kit gene in the spectrum of GISTs, including benign, borderline, and malignant variants from different sites. The sequences of c-kit gene were also evaluated in typical smooth muscle tumors, schwannomas and other tumors, especially in 4 adenocarcinmas accompanied by GISTs.
Our series of 52 benign, borderline, and malignant GISTs showed that 96.2% of the GISTs expressed CD117 and only some of the GISTs had mutations. The results indicated a considerable proportion of GISTs expressed CD117 with no mutation. In other words, most of c-kit mutations did not affect the proportion of GISTs with CD117 expression. Mutations in exon 11 of the c-kit gene were observed in 56% of malignant cases. In constrast, only 2 borderline GISTs (10.5%) showed mutations, and no benign GISTs showed mutations, suggesting that the mutations of exon 11 of the c-kit gene may represent a genotypic marker with a correlation to malignancy.
Lasota and colleagues [13] reported the mutation of exons 9 and 13, but the mutation rate seemed to be very low, and they only detected the small portion (8%) of mutations of GISTs in exons 9 and 13, which did not have mutations in exon 11 of the c-kit gene. In our series, no mutations were detected. The result also indicated the rates of mutations in other regions of the c-kit gene were very low.
Our present results were in accordance with those previously reported [14] [15] [16] . In hot spot region of exon 11 involving codons 550-560, point mutation and frame deletion were mainly detected at these codons, and 2 cases showed homozygous deletions.
In addition to the change at codons of 550-560, however, the duplication mutation fashion was found in 3 cases to cluster at codons 570 to 585, which was rarely detected in the previously reports.
Analysis of c-kit mutation pattern in relapse lesions showed the persistence of the mutation that remained identical in the primary lesion. Therefore, the c-kit mutation pattern could be tumor-specific.
C-kit mutations were never observed in smooth muscle tumors or nerve sheath tumors or other soft tissue tumors. Furthermore, one adenocarcinoma accompanied by mutationpositive GIST was the wild-type c-kit gene. Therefore, c-kit mutations may also represent a genotypic lineage marker for GISTs.
Previous and present molecular studies have revealed the gain-of-function mutations of the c-kit gene could be observed in mast cell neoplasms [17, 18] , human germ cell tumors [19] and GISTs, but the location of c-kit mutations differs in them. The particular aspartic acid in the tyrosine kinase domain would changes into valine in mast cell neoplasms, The aspartic acid at amino acid position 816 would change into histidine, whereas deletion, point mutation, or both in the juxtamembrane domain were observed in GISTs mutations. Specially, the mutations were located within codons 550 to 560 in exon 11, and rare mutations are detectable in other domains of the c-kit gene, such as exons 9, 13. Clustering of c-kit mutations in the same region of GISTs and in different region with mast cell neoplasm supported their specific biological significance. The occurrence of activating mutations involving exon 11 of the c-kit gene in sporadic GIST and the association of exon 11 germline mutations in familial GISTs indicated they were important in GIST's tumorigenesis [20] . Especially, c-kit mutations could be detected only in some of GISTs [21, 22] , so the value of the c-kit gene mutation in GISTs inspired the researchers, but there are no concordant conclusions, reports regarding the frequency of mutations in exon 11 varied widely, and prognostic significance of c-kit mutations with respect to the association between exon 11 mutations and malignant histology and/or aggressive malignant behavior were conflicting, and the reported frequency of these mutations varied over a wide range [23] [24] [25] [26] [27] [28] [29] . Taniguchi and colleagues [23] found that c-kit mutation-positive GIST were worse than c-kit mutation-negative GISTs. But other studies showed that c-kit exon 11 mutation analysis did not correlate well with histological assessment of malignant potential, and could not be regarded as a reliable objective marker for poor prognosis in GISTs.
Some malignant GISTs lack of exon 11 mutation suggested that mutations in exon 11 of c-kit gene were not the only mechanisms related to malignancy and there must exist other molecular mechanisms [30] [31] [32] [33] , which may include mutations in other regions of the c-kit gene. But previous report and our study indicated other region mutation of the c-kit gene was few. Recently, Heihrich and colleagues [34] have made an important finding in GISTs, they reported that 35% (14/40) of GISTs lacking c-kit mutations had intragenic activation mutations in tyrosine kinase, platelet-derived growth factor (PDGFRA). C-kit gene and PDGFRA mutations appeared to be alternative and mutually exclusive in GISTs, further study is needed to understand the role of PDGFRA in GISTs.
In summary, the results showed a consistent c-kit expression in GISTs with or without detectable mutations. The mutations occurred more preferentially in malignant GISTs than versus in benign GISTs, but not in smooth muscle tumor and other tumors. These observations suggest that mutations in exon 11 of the c-kit gene might represent useful molecular genetic markers for malignant GISTs and help to differentiate GIST from other tumors. Whether the c-kit gene mutation can indicate bad prognosis of malignant GISTs needs to be further studied.
